Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing investment in research and development
3.2.1.2 Growing burden of HIV
3.2.1.3 Increase in availability of novel drugs for treatment of HIV
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with the drugs
3.2.2.2 High cost of the treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 – 2032 ($ Million)
5.1 Key trends
5.2 Protease inhibitors
5.3 Integrase inhibitors
5.4 Multi-class combination products
5.5 Nucleoside reverse transcriptase inhibitors (NRTIs)
5.6 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
5.7 Other drug classes
Chapter 6 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Million)
6.1 Key trends
6.2 Branded
6.3 Generic
Chapter 7 Market Estimates and Forecast, By Age Group, 2018 – 2032 ($ Million)
7.1 Key trends
7.2 Adult
7.3 Pediatric
7.4 Geriatric
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Million)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Boehringer Ingelheim International GmbH
10.3 Bristol-Myers Squibb Company
10.4 Cipla
10.5 F. Hoffmann-La Roche Ltd
10.6 Gilead Sciences, Inc.
10.7 GlaxoSmithKline plc.
10.8 Johnson and Johnson
10.9 Merck & Co, Inc.
10.10 Pfizer Inc.
10.11 Viatris Inc.
